Publications by authors named "Edwin M Spithoven"

Claim this Profile
E
Epidemiology and Clinical Impact of Confirmed Respiratory Viral Infections in Solid Organ Transplant Recipients.
Manon L M Prins, Ernst D van Dokkum, Aiko P J de Vries, Maarten E Tushuizen, Danny van der Helm, Edwin M Spithoven

Transpl Infect Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Influenza Among Immunocompromised Adults With a Solid Organ Transplant.
Manon L M Prins, Ernst D van Dokkum, Aiko P J de Vries, Maarten E Tushuizen, Danny van der Helm, Edwin M Spithoven

Transpl Int· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unilateral Pleural Effusion in a Hemodialysis Patient.
Edwin M Spithoven, Alferso C Abrahams

Kidney360· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
Rene M M van Aerts, Wietske Kievit, Hedwig M A D'Agnolo, Charles J Blijdorp, Niek F Casteleijn, Edwin M Spithoven

Gastroenterology· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a Somatostatin Analogue on the Vasopressin Pathway in Patients With ADPKD.
A Lianne Messchendorp, Bart J Kramers, Edwin M Spithoven, Katrin Stade, Esther Meijer

Kidney Int Rep· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
A Lianne Messchendorp, Edwin M Spithoven, Niek F Casteleijn, Wendy A Dam, Jacob van den Born

BMC Nephrol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
Esther Meijer, Folkert W Visser, Rene M M van Aerts, Charles J Blijdorp, Niek F Casteleijn, Edwin M Spithoven

JAMA· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease.
Hedwig M A D'Agnolo, Niek F Casteleijn, Tom J G Gevers, Hans de Fijter, Maartje D A van Gastel, Edwin M Spithoven

Am J Nephrol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression.
A Lianne Messchendorp, Esther Meijer, Wendy E Boertien, Gerwin E Engels, Niek F Casteleijn, Edwin M Spithoven

Kidney Int Rep· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study.
Marten A Lantinga, Hedwig M A D'Agnolo, Niek F Casteleijn, Johan W de Fijter, Esther Meijer, Edwin M Spithoven

Drug Saf· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?
Niek F Casteleijn, Debbie Zittema, Stephan J L Bakker, Wendy E Boertien, Carlo A Gaillard, Edwin M Spithoven

Am J Nephrol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation of total kidney volume in autosomal dominant polycystic kidney disease.
Edwin M Spithoven, Maatje D A van Gastel, A Lianne Messchendorp, Niek F Casteleijn, Joost P H Drenth

Am J Kidney Dis· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Authors Reply.
Edwin M Spithoven, Ron T Gansevoort

Kidney Int· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bilateral cysts in the choroid plexus in a patient with autosomal dominant polycystic kidney disease.
Niek F Casteleijn, Edwin M Spithoven, Maarten B Rookmaaker, Mervyn D I Vergouwen, Ron T Gansevoort

Nephrol Dial Transplant· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease.
Edwin M Spithoven, Anneke Kramer, Esther Meijer, Bjarne Orskov, Christoph Wanner

Kidney Int· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry.
Edwin M Spithoven, Anneke Kramer, Esther Meijer, Bjarne Orskov, Christoph Wanner

Nephrol Dial Transplant· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nephrectomy in autosomal dominant polycystic kidney disease: a patient with exceptionally large, still functioning kidneys.
Edwin M Spithoven, Niek F Casteleijn, Paul Berger, Roel Goldschmeding

Case Rep Nephrol Urol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
Esther Meijer, Joost P H Drenth, Hedwig d'Agnolo, Niek F Casteleijn, Johan W de Fijter, Edwin M Spithoven

Am J Kidney Dis· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.
Edwin M Spithoven, Esther Meijer, Wendy E Boertien, Steef J Sinkeler, Hilde Tent

Am J Kidney Dis· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular screening in general practice in a low SES area.
Ans H Tiessen, Andries J Smit, Sebes Zevenhuizen, Edwin M Spithoven, Klaas Van der Meer

BMC Fam Pract· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis